Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: from pharmacophore-based virtual screening to molecular dynamics

The lack of effective treatment remains the biggest bottleneck in combating the current novel coronavirus (COVID-19) pandemic. Drug discovery is a complex and time-consuming process, while various in silico methods dramatically reduce the time and cost of this process. The infection begins with the binding of the receptor-binding domain (RBD) of Spike (S) glycoprotein from SARS-CoV-2 to the host angiotensin-converting enzyme (ACE2) receptor. We, therefore, present computational screening methods aimed to identify inhibitors potentially able to target RBD. For this purpose, pharmacophore mapping, molecular docking, and molecular dynamics (MD) simulations were performed to screen potential candidates against ACE2/SARS-CoV-2. In particular, pharmacophore-based virtual screening used over a hundred million compounds to construct protein-protein interactions (PPIs) inhibitor library. In conclusion, PubChem-84280085 compound is suggested as a potential PPIs inhibitor for preventing SARS-CoV-2 RBD/ACE2 interactions.

[1]  Shada J Alabed,et al.  Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies , 2020, Acta pharmaceutica.

[2]  Pramod C. Nair,et al.  An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. , 2011, Journal of chemical theory and computation.

[3]  Junmei Wang,et al.  End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. , 2019, Chemical reviews.

[4]  B. Fielding,et al.  Coronavirus envelope protein: current knowledge , 2019, Virology Journal.

[5]  P. Hsueh,et al.  Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV , 2020, Journal of Microbiology, Immunology and Infection.

[6]  Benjamin A. Shoemaker,et al.  PubChem in 2021: new data content and improved web interfaces , 2020, Nucleic Acids Res..

[7]  Daisuke Kihara,et al.  In silico structure-based approaches to discover protein-protein interaction-targeting drugs. , 2017, Methods.

[8]  Rajendra Kumar,et al.  g_mmpbsa - A GROMACS Tool for High-Throughput MM-PBSA Calculations , 2014, J. Chem. Inf. Model..

[9]  Andreas P. Eichenberger,et al.  Definition and testing of the GROMOS force-field versions 54A7 and 54B7 , 2011, European Biophysics Journal.

[10]  N. Shrivastava,et al.  Pharmacophore modeling, molecular docking and molecular dynamics simulation for screening and identifying anti-dengue phytocompounds , 2019, Journal of biomolecular structure & dynamics.

[11]  Yumin Li,et al.  Molecular dynamics simulation studies on Ca2+ -induced conformational changes of annexin I. , 2008, Protein engineering, design & selection : PEDS.

[12]  Anand Anbarasu,et al.  Computational Analysis Reveals the Association of Threonine 118 Methionine Mutation in PMP22 Resulting in CMT-1A , 2014, Adv. Bioinformatics.

[13]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[14]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[15]  J. Abhithaj,et al.  Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target , 2020, Journal of biomolecular structure & dynamics.

[16]  Denis J. Evans,et al.  The Nose–Hoover thermostat , 1985 .

[17]  H. Zali,et al.  Cancer Care Management During the COVID-19 Pandemic , 2020, Risk management and healthcare policy.

[18]  David Ryan Koes,et al.  PocketQuery: protein–protein interaction inhibitor starting points from protein–protein interaction structure , 2012, Nucleic Acids Res..

[19]  H. Zali,et al.  Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach , 2021, Biomedicine & Pharmacotherapy.

[20]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[21]  David Ryan Koes,et al.  Pharmit: interactive exploration of chemical space , 2016, Nucleic Acids Res..

[22]  Robert Kiss,et al.  http://Mcule.com: a public web service for drug discovery , 2012, Journal of Cheminformatics.

[23]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[24]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[25]  COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2 , 2020, PLoS pathogens.

[26]  Shuwen Liu,et al.  Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.

[27]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[28]  P. Młynarz,et al.  Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus , 2020, Journal of Functional Foods.

[29]  C. Pathak,et al.  Structural insights into pharmacophore-assisted in silico identification of protein–protein interaction inhibitors for inhibition of human toll-like receptor 4 – myeloid differentiation factor-2 (hTLR4−MD-2) complex , 2018, Journal of biomolecular structure & dynamics.

[30]  Tiziano Tuccinardi,et al.  Application of MM-PBSA Methods in Virtual Screening , 2020, Molecules.

[31]  S. Cho,et al.  Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation , 2020, Scientific Reports.

[32]  C. Leung,et al.  Mimicking Strategy for Protein–Protein Interaction Inhibitor Discovery by Virtual Screening , 2019, Molecules.

[33]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[34]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[35]  I. Qureshi,et al.  Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches , 2020, Journal of biomolecular structure & dynamics.

[36]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[37]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[38]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[39]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[40]  Maria Rita Gulotta,et al.  Targeting SARS‐CoV‐2 RBD Interface: a Supervised Computational Data‐Driven Approach to Identify Potential Modulators , 2020, ChemMedChem.

[41]  G. Klebe,et al.  Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. , 2002, Angewandte Chemie.